Markets HCW ups Capricor Therapeutics PT to $12.40 from $3.50 H.C. Wainwright raised its price target for Capricor Therapeutics (NASDAQ:CAPR) to $12.40 from $3.50 after the company posted positive results from an interim analysis of the HOPE-2 trial in patients with Duchenne... July 16, 2019